Clinical Trial Update: Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Erlotinib in adults with unresectable hepatocellular carcinoma, cholangiocarcinoma, or gallbladder cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED